Literature DB >> 21602008

Incidental adrenal lesions: Accuracy of quadriphasic contrast enhanced computed tomography in distinguishing adenomas from nonadenomas.

Giovanni Foti1, Niccolò Faccioli, William Mantovani, Giuseppe Malleo, Riccardo Manfredi, Roberto Pozzi Mucelli.   

Abstract

PURPOSE: To evaluate the accuracy in distinguishing adrenal adenomas from nonadenomas by means of quadriphasic CT exam, including unenhanced (UE), arterial enhanced (AE), portal enhanced (PE) and 5-min delayed enhanced (DE) CT scans.
METHODS: This retrospective study had institutional review board approval; the need for informed consent was waived. From September 2007 to September 2009, 104 adrenal masses were evaluated in 87 patients (49 M, 38 F, mean age 58.4 years) undergoing UE, AE (35-s delay), PE (80-s delay) and DE (5-min delay) CT scans. The mean adrenal attenuation during all imaging phases was measured by two readers. The accuracy values of absolute unenhanced attenuation (UE), absolute wash-out (AWO), relative percentage wash-out (RPWO) and percentage enhancement wash-out (PEW) were assessed by using receiver operator curves (ROC) analysis. The overall accuracy of the quadriphasic protocol and other triphasic protocols were evaluated. A value of p≤0.05 was considered significant.
RESULTS: The accuracy in characterizing adrenal lesions was 86.5% (90/104) for UE attenuation (≤10 HU threshold), 90.1% (82/91) for RPWO (≥30% threshold), 85.7% (78/91) for AWO (≥12 HU threshold) and 83.5% (76/91) for PEW (≥30% threshold), respectively. Quadriphasic CT (accuracy 97.1%, 101/104) performed better than triphasic CT including only AE scan (efficiency 90.0%, 94/104; p=0.011) and triphasic CT including only PE scan (efficiency 96.1%, 100/104; p=0.025).
CONCLUSION: Quadriphasic CT protocol including 5-min DE scan may be used to characterize incidentally detected adrenal masses. RPWO represented the best wash-out parameter for characterizing adrenal lesions.
Copyright © 2011 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21602008     DOI: 10.1016/j.ejrad.2011.04.066

Source DB:  PubMed          Journal:  Eur J Radiol        ISSN: 0720-048X            Impact factor:   3.528


  6 in total

1.  Dual adrenal venous phase contrast-enhanced MDCT for visualization of right adrenal veins in patients with primary aldosteronism.

Authors:  Satoru Morita; Yu Nishina; Hiroshi Yamazaki; Yasuyuki Sonoyama; Atsuhiro Ichihara; Shuji Sakai
Journal:  Eur Radiol       Date:  2015-10-22       Impact factor: 5.315

2.  Characterization of adrenal lesions using MDCT wash-out parameters: diagnostic accuracy of several combinations of intermediate and delayed phases.

Authors:  Giovanni Foti; Giuseppe Malleo; Niccolò Faccioli; Andrea Guerriero; Lino Furlani; Giovanni Carbognin
Journal:  Radiol Med       Date:  2018-06-19       Impact factor: 3.469

3.  Cross-sectional imaging work-up of adrenal masses.

Authors:  Brinda Rao Korivi; Khaled M Elsayes
Journal:  World J Radiol       Date:  2013-03-28

4.  Utility of Intermediate-Delay Washout CT Images for Differentiation of Malignant and Benign Adrenal Lesions: A Multivariate Analysis.

Authors:  Chaan S Ng; Emre Altinmakas; Wei Wei; Payel Ghosh; Xiao Li; Elizabeth G Grubbs; Nancy D Perrier; Jeffrey E Lee; Victor G Prieto; Brian P Hobbs
Journal:  AJR Am J Roentgenol       Date:  2018-06-27       Impact factor: 3.959

5.  MDCT in the differentiation of adrenal masses: comparison between different scan delays for the evaluation of intralesional washout.

Authors:  Giuseppe Angelelli; Maria Elisabetta Mancini; Marco Moschetta; Pasquale Pedote; Pasquale Pignataro; Arnaldo Scardapane
Journal:  ScientificWorldJournal       Date:  2013-03-07

6.  Characteristics of Adrenal Incidentalomas in a Large, Prospective Computed Tomography-Based Multicenter Study: The COAR Study in Korea.

Authors:  Seong Hee Ahn; Jae Hyeon Kim; Seung Hee Baek; Hyeonmok Kim; Yoon Young Cho; Sunghwan Suh; Beom Jun Kim; Seongbin Hong; Jung Min Koh; Seung Hun Lee; Kee Ho Song
Journal:  Yonsei Med J       Date:  2018-06       Impact factor: 2.759

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.